The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial
Open accessAbstract
Importance: Anxiety disorders are common, highly distressing, and impairing conditions. Effective treatments exist, but many patients do not access or respond to them. Mindfulness-based interventions, such as mindfulness-based stress reduction (MBSR) are popular and can decrease anxiety, but it is unknown how they compare to standard first-line treatments. Objective: To determine whether MBSR is noninferior to escitalopram, a commonly used first-line psychopharmacological treatment for anxiety disorders. Design, Setting, and Participants: This randomized clinical trial (Treatments for Anxiety: Meditation and Escitalopram [TAME]) included a noninferiority design with a prespecified noninferiority margin. Patients were recruited between June 2018 and February 2020. The outcome assessments were performed by blinded clinical interviewer at baseline, week 8 end point, and follow-up visits at 12 and 24 weeks. Of 430 individuals assessed for inclusion, 276 adults with a diagnosed anxiety disorder from 3 urban academic medical centers in the US were recruited for the trial, and 208 completed the trial. Interventions: Participants were 1:1 randomized to 8 weeks of the weekly MBSR course or the antidepressant escitalopram, flexibly dosed from 10 to 20 mg. Main Outcomes and Measures: The primary outcome measure was anxiety levels as assessed with the Clinical Global Impression of Severity scale (CGI-S), with a predetermined noninferiority margin of −0.495 points. Results: The primary noninferiority sample consisted of 208 patients (102 in MBSR and 106 in escitalopram), with a mean (SD) age of 33 (13) years; 156 participants (75%) were female; 32 participants (15%) were African American, 41 (20%) were Asian, 18 (9%) were Hispanic/Latino, 122 (59%) were White, and 13 (6%) were of another race or ethnicity (including Native American or Alaska Native, more than one race, or other, consolidated owing to low numbers). Baseline mean (SD) CGI-S score was 4.44 (0.79) for the MBSR group and 4.51 (0.78) for the escitalopram group in the per-protocol sample and 4.49 (0.77) vs 4.54 (0.83), respectively, in the randomized sample. At end point, the mean (SD) CGI-S score was reduced by 1.35 (1.06) for MBSR and 1.43 (1.17) for escitalopram. The difference between groups was −0.07 (0.16; 95% CI, −0.38 to 0.23; P = .65), where the lower bound of the interval fell within the predefined noninferiority margin of −0.495, indicating noninferiority of MBSR compared with escitalopram. Secondary intent-to-treat analyses using imputed data also showed the noninferiority of MBSR compared with escitalopram based on the improvement in CGI-S score. Of patients who started treatment, 10 (8%) dropped out of the escitalopram group and none from the MBSR group due to adverse events. At least 1 study-related adverse event occurred for 110 participants randomized to escitalopram (78.6%) and 21 participants randomized to MBSR (15.4%). Conclusions and Relevance: The results from this randomized clinical trial comparing a standardized evidence-based mindfulness-based intervention with pharmacotherapy for the treatment of anxiety disorders found that MBSR was noninferior to escitalopram. Trial Registration: ClinicalTrials.gov Identifier: NCT03522844
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meditation Programs for Psychological Stress and Well-being: A Systematic Review and Meta-analysis
Goyal, M., Singh, S., Sibinga, E. M. S., Gould, N. F., Rowland-Seymour, A., Sharma, R., Berger, Z., Sleicher, D., Maron, D. D., Shihab, H. M., et al. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.13018 · Cited by 2,380
How does mindfulness-based cognitive therapy work?
Kuyken, W., Watkins, E., Holden, E., White, K., Taylor, R. S., Byford, S., Evans, A., Radford, S., Teasdale, J. D., & Dalgleish, T. (2010) · Behaviour Research and Therapy · doi:10.1016/j.brat.2010.08.003 · Cited by 809
Development and validation of an Overall Anxiety Severity and Impairment Scale (OASIS)
Norman, S. B., Hami Cissell, S., Means-Christensen, A. J., & Stein, M. B. (2006) · Depression and Anxiety · doi:10.1002/da.20182 · Cited by 770
Ramel1, W., Goldin, P. R., Carmona, P. E., & McQuaid, J. R. (2004) · Cognitive Therapy and Research · doi:10.1023/b:cotr.0000045557.15923.96 · Cited by 580
Mind the gap: improving the dissemination of CBT
Shafran, R., Clark, D. M., Fairburn, C. G., Arntz, A., Barlow, D. H., Ehlers, A., Freeston, M., Garety, P. A., Hollon, S. D., Ost, L. G., et al. (2009) · Behaviour Research and Therapy · doi:10.1016/j.brat.2009.07.003 · Cited by 569
Hoge, E. A., Bui, E., Marques, L., Metcalf, C. A., Morris, L. K., Robinaugh, D. J., Worthington, J. J., Pollack, M. H., & Simon, N. M. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08083 · Cited by 511
Self-citationMindfulness and emotion regulation
Roemer, L., Williston, S. K., & Rollins, L. G. (2015) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2015.02.006 · Cited by 411
Nepon, J., Belik, S.-L., Bolton, J., & Sareen, J. (2010) · Depression and Anxiety · doi:10.1002/da.20674 · Cited by 374
Haller, H., Breilmann, P., Schröter, M., Dobos, G., & Cramer, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-99882-w · Cited by 126
Research works printed but not linked: 12
- Ormel, 1994, Common mental disorders and disability across cultures. results from the WHO Collaborative Study on Psychological Problems in General Health Care., JAMA, 272, 1741, 10.1001/jama.1994.03520220035028 · DOI · Paper page
- Croghan, 2003, American attitudes toward and willingness to use psychiatric medications., J Nerv Ment Dis, 191, 166, 10.1097/01.NMD.0000054933.52571.CA · DOI
- Mullins, 2006, Comparison of first refill rates among users of sertraline, paroxetine, and citalopram., Clin Ther, 28, 297, 10.1016/j.clinthera.2006.02.006 · DOI
- Clarke, 2018, Use of yoga, meditation, and chiropractors among US adults aged 18 and over., NCHS Data Brief, 1
- Hoge, 2020, Treatment for anxiety: mindfulness meditation versus escitalopram (TAME): design of a randomized, controlled non-inferiority trial., Contemp Clin Trials, 91, 10.1016/j.cct.2020.105965 · DOI
- Sheehan, 1998, The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10., J Clin Psychiatry, 59, 22
- Crovetto, 2021, Effects of Mediterranean diet or mindfulness-based stress reduction on prevention of small-for-gestational age birth weights in newborns born to at-risk pregnant individuals: the IMPACT BCN randomized clinical trial., JAMA, 326, 2150, 10.1001/jama.2021.20178 · DOI
- Davidson, 2004, Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study., Depress Anxiety, 19, 234, 10.1002/(ISSN)1520-6394 · DOI · Paper page
- Asakura, 2016, Long-term administration of escitalopram in patients with social anxiety disorder in Japan., Neuropsychiatr Dis Treat, 12, 1817, 10.2147/NDT · DOI · Paper page
- Costa, 2021, A three-arm randomized clinical trial comparing the efficacy of a mindfulness-based intervention with an active comparison group and fluoxetine treatment for adults with generalized anxiety disorder., Psychother Psychosom, 90, 269, 10.1159/000511880 · DOI
- Guy, 1976, ECDEU Assessment Manual for Psychopharmacology
- Rothmann, 2012, Design and Analysis of Non-Inferiority Trials
Cited by
Szuhany, K. L., & Simon, N. M. (2022) · JAMA · doi:10.1001/jama.2022.22744 · Cited by 541
Self-citationCarlson, L. E., Ismaila, N., Addington, E. L., Asher, G. N., Atreya, C., Balneaves, L. G., Bradt, J., Fuller-Shavel, N., Goodman, J., Hoffman, C. J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00857 · Cited by 309
Domschke, K., Seuling, P. D., Schiele, M. A., Bandelow, B., Batelaan, N. M., Bokma, W. A., Branchi, I., Broich, K., Burkauskas, J., Davies, S. J. C., et al. (2024) · World Psychiatry · doi:10.1002/wps.21177 · Cited by 46
Li, Y., He, M., Wang, Z., Hofmann, S. G., & Liu, X. (2024) · International Journal of Clinical and Health Psychology · doi:10.1016/j.ijchp.2024.100445 · Cited by 22
Wang, M., Zhang, H., Zhang, X., Zhao, Q., Chen, J., Hu, C., Feng, R., Liu, D., Fu, P., Zhang, C., et al. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.03.009 · Cited by 21
Metadata
- Authors
- Hoge, E. A., Bui, E., Mete, M., Dutton, M. A., Baker, A. W., & Simon, N. M.
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2023-01-01
- Volume
- 80
- Issue
- 1
- Pages
- 13
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W4308638987
- Cited by
- 182
- References
- 10
- FWCI
- 29.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamapsychiatry.2022.3679
- The paper
- Hoge, E. A., Bui, E., Mete, M., Dutton, M. A., Baker, A. W., & Simon, N. M. (2023). Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2022.3679
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.